Back to Search Start Over

Paliperidone palmitate versus other antipsychotics.

Authors :
Hervías Higueras, P.
Maroto Martín, L.
Raffo Moncloa, S.
Leonor del Pozo, M.
Source :
European Psychiatry. Mar2016 Supplement, Vol. 33, pS674-S675. 1p.
Publication Year :
2016

Abstract

The aim of the study was to describe the psychopharmacological treatments received by inpatients diagnosed with spectrum disorders schizophrenia and other psychotic disorders in Dr. Rodriguez Lafora Hospital. It is an observational, descriptive and retrospective study. We collected information about patients aged 18 to 64 who were hospitalized during the month of January of 2015 in the acute psychiatric hospitalization by Selene software. We reviewed treatments and number of psychiatric re-hospitalization six months later and we analyzed the results by SPSS software. From a sample of 51 inpatients, 15 of them were diagnosed with disorders of the spectrum of schizophrenia and other psychotic disorders. Of the patients, 13.3% was treated with haloperidol, 26.7% with olanzapine, 26.7% with risperidone although it was modified by paliperidone in mental health center, 6.7% with quetiapine, 6.7% with amisulpride, 13.3% with oral paliperidone and 13.3% patients with intramuscular paliperidone. Of these, 40% are readmitted to hospital. Patients were readmitted due to ineffectiveness and adverse effects of haloperidol, olanzapine, risperidone. 73.3% of inpatients were treated with monotherapy. Of the patients, 26.7% were treated with polytherapy, who received olanzapine, risperidone and amisulpride. It would be important to use psychoactive substances that allow monotherapy to reduce adverse effects and psychiatric re-hospitalization. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09249338
Volume :
33
Database :
Academic Search Index
Journal :
European Psychiatry
Publication Type :
Academic Journal
Accession number :
113406723
Full Text :
https://doi.org/10.1016/j.eurpsy.2016.01.2003